

2025 ANNUAL IMPACT REPORT



Letter

FROM THE BOARD OF DIRECTORS

Dear Friends and Supporters:

In 2025, Aamed Alliance continued to advocate for upholding, enforcing, and expanding consumer protections under the Employee Retirement Income and Security Act (ERISA); the Food, Drug, and Cosmetic Act (FD&C Act); the Patient Protection and Affordable Care Act (ACA); and the Unfair and Deceptive Trade Practices Act (FTC Act), and for addressing the needs of patients, caregivers, and health care providers.

Throughout the year, Aamed Alliance conducted original, in-depth research on the state of utilization management and emphasized the urgent need for robust oversight by state insurance commissioners and regulators to protect patients, providers, and caregivers. Our team identified, developed, and shared sound, patient-centered policy recommendations grounded in legal and regulatory analysis and shared those recommendations with state legislators, regulators, and policymakers. In parallel, Aamed Alliance staff also worked closely with patient and provider advocacy organizations to convey shared concerns regarding patient access, affordability, and innovation. This work included presenting research findings and policy analysis to a wide range of stakeholders, collaborating with like-minded organizations, and maintaining ongoing engagement with local, state, and federal policymakers

In 2026, Aamed Alliance will continue to advocate for upholding, enforcing, and expanding health care consumer protections, including step therapy reform, protecting access for individuals with serious mental illnesses and rare disorders, promoting fair and transparent prescription drug pricing, and ensuring oversight of the use of artificial intelligence within health insurance and health care. We look forward to continuing our work to protect and enhance the rights of health care consumers and providers.

Sincerely,

- Eifer Goldberg

Director

- Andrew Losinger

Director

- Mark Estock, RN

Director



KEY STAFF



ASHIRA VANTREES, ESQ.

Ashira Vantrees, Esq., is the Director of Legal Strategy and Advocacy at Aimed Alliance. Ms. Vantrees provides unique strategic planning and legal insights through research and analysis of laws, regulations, legislation, and advocacy initiatives. Ms. Vantrees also leads the organization's work relating to new and emerging health policy issues. Ms. Vantrees brings with her extensive experience in researching a wide variety of issues, including public health, health education, health law, human rights, women's rights, and disability rights. She is a member of the DC Bar and Florida Bar.



MICHAEL BARNES, ESQ.

Michael C. Barnes, Esq., provides outside legal counsel to Aimed Alliance. He is also Managing Attorney at Sequel Health Law, where he practices health and drug law and policy. Mr. Barnes advises commercial, professional, academic, and not-for-profit clients on legal and regulatory matters involving opioids, cannabinoids, access to treatment, insurance coverage and payment, parity, privacy, digital health, health information exchange, recovery in the workplace, and correctional health care, among other topics. He is also Chairman of the Center for U.S. Policy and a member of the advisory board for the Rx and Illicit Drug Summit, the board of directors for the Legislative Analysis and Public Policy Association, and the editorial board for the Journal of Opioid Management. Mr. Barnes is licensed to practice law in the District of Columbia and Virginia.



OLIVIA BACKHAUS, ESQ.

Olivia Backhaus, Esq., is Staff Attorney at Aimed Alliance. Ms. Backhaus provides legal counsel and helps lead the organization's work on prescription drug affordability boards. Prior to joining Aimed Alliance, Ms. Backhaus was an Associate at Sequel Health Law, where she gained practical experience in policy advocacy and legislative research and strategy. She earned her J.D. from Georgetown University Law Center. She received a bachelor's degree in biology from Sewanee: The University of the South. Ms. Backhaus is a member of the DC Bar.



TABLE OF CONTENTS

Advocacy	6
Research & Analysis.....	11
Thought Leadership	15
Organizational Collaboration.....	18

BELIEFS

We believe that Americans should value their health care and prioritize it as consumers. We believe that health care industry stakeholders should place the health and safety of patients above all other considerations. We believe that the costs of health care services should be reasonable and transparent.

MISSION

Aimed Alliance is a 501(c)(3) not-for-profit health policy organization. The mission of Aimed Alliance is to protect and enhance the rights of health care consumers and providers.

VISION

The vision of Aimed Alliance is a society in which consumers, in consultation with their health care providers and loved ones, can make informed and individually appropriate decisions about their health care, and those decisions are not overridden by third parties.



2025 BY THE NUMBERS

17 

New Publications

22 

Speaking engagements

277 

State & Local Legislators Reached Through Presentations

69 

Letters & Comments

16 

Sign-On Letters

90 

Health News Summaries Published

7 

State Legislative Tracking Maps

4 

Citations in the Media

64 

Consumers Assisted


618,000+
Social Media Impressions



Advocacy

AIMED ALLIANCE WORKED ON THE FOLLOWING ISSUES IN 2025:



Encouraged federal action to address non-essential health benefit (non-EHB) and alternative funding programs (AFPs).



Assisted 64 consumers in navigating health insurance appeals and insurance questions.



Educated patient and provider groups about copay accumulators, non-EHB schemes and AFPs.



Educated state legislators and consumers on step therapy reform trends and best practices.



Launched Judicial Advocacy Working Group to expand the capacity of patient advocacy organizations to engage in litigation and amicus briefs.



Facilitated and hosted meeting with the Center for Consumer Information and Insurance Oversight (CCIIO), Department of Labor (DOL) and Department of Health and Human Services (HHS) regarding essential health benefits and alternative funding programs.



Urged State Insurance Commissioners to enforce the 2020 Notice of Benefit and Payment Parameters copay assistance protections, and state-based statutory protections.



Ensured Florida health plans complied with state law banning the use of mandated specialty pharmacies.



Published 50-State Report highlighting step therapy reforms, oversight practices, and AI regulation within health insurance.



Educated patients, providers, and advocacy organizations on the role of the United States Trade Representative (USTR) in trade of health care supplies and prescription drugs.



Advocacy HIGHLIGHTS

Aimed Alliance supports laws, regulations, and policies that encourage or require public and private payers to provide access to high-quality, individualized, culturally appropriate, efficient, and transparent health care.

Aimed Alliance also supports curtailing the use of discriminatory practices in the delivery of health care and the administration of health insurance and employee benefits. To accomplish these goals, Aimed Alliance educates patients, providers, employers, policymakers, and other stakeholders.



RESEARCH RESULTS

[Understanding Step Therapy Reform: A 50 State Analysis of Best Practices and Opportunities](#)

The Issue:

Step therapy policies, also known as “fail first,” are used by insurers and pharmacy benefit managers (PBMs) to require consumers to try and fail on alternative treatments, before the insurer or PBM will cover the originally prescribed treatment. As a result, treatments that may be most effective at treating a condition may be inaccessible to consumers until alternative treatments are proven ineffective. Without proper guardrails, step therapy policies may also require patients to try and fail on off-label treatments, multiple different treatments, and treatments consumers have previously failed on under a different health plan. Policies can also require consumers to try and fail a treatment for more than 30 days, forcing consumers to continue to experience symptoms without relief. As of 2025, [thirty-eight states](#) have passed some type of step therapy reform. Despite these protections there are still gaps in step therapy reform.



Our Work:

Since 2018, Aimed Alliance has led the New York Step Therapy Alliance, a group of nonprofit patient advocacy organizations, professional associations, regulators, and legislative officials working together to determine how the New York step therapy law can be improved to better protect patients' access to their necessary medications, and to ensure that bad actors that violate the step therapy law are held accountable. With the support of the New York Step Therapy Alliance, the New York Legislature passed reforms in [2023](#) and [2024](#). To better understand how other states were ensuring step therapy laws were effective and filling regulatory gaps, Aimed Alliance conducted a 50-state analysis to determine (1) best practices in step therapy reform; (2) how states were exercising oversight authority; and (3) how states were beginning to regulate the use of AI within health insurance.

Outcome:

In June 2025, Aimed Alliance published the [2025 State Report: Step Therapy, Oversight, and Artificial Intelligence: Trends and Best Practices](#). The Report highlights emerging step therapy trends such as banning the use of step therapy for serious mental illness and stage 3 and 4 cancers, limiting time periods of failure, and imposing response timelines for exception requests. The Report findings were shared at the [2025 National Foundation for Women Legislatures Health Care Summit](#), the [2025 Democratic Legislative Campaign Committee \(DLCC\) Annual Meeting](#), and the [78th Annual Council of State Governments West Meeting](#).

REGULATORY SUCCESS

Upholding Enacted Consumer and Provider Protections in Florida

The Issue:

In 2023, the Florida Legislature passed the [Prescription Drug Reform Act](#). Florida's Prescription Drug Reform Act applies to all health plans, entities providing pharmacy benefits, and entities acting on behalf of the pharmacy benefits plan or program. The law prohibits requiring a covered person to obtain in-person physician-administered prescription drugs from a specific affiliated pharmacy, essentially prohibiting mandated specialty pharmacies.

Our Work:

Aimed Alliance identified two separate health plan policies that required consumers to brown-bag their medications from specific pharmacies. Based on Aimed Alliance's analysis, this mandated use of specific pharmacies was inconsistent with Florida's Prescription Drug Reform Act. To address this issue, Aimed Alliance sent letters to each health plan explaining our understanding of the policy and compliance with state law.

Outcome:

In response to Aimed Alliance letters urging the health plans to comply with state law, both health plans reversed their policies.



ADVOCACY, COMMENTS, & LETTERS










Additional 2025 federal and state advocacy efforts included the following:

STATE

-  18 Letters to State Insurance Commissioners Without Copay Accumulator Bans Requesting Enforcement of 2020 NBPP and 2023 District Court Decision
-  11 Letters to State Insurance Commissioners Regarding Enforcing State Bans on Copay Accumulators in Response to 2025 TAI Report
-  [Letter](#) in Support of MO Copay Accumulator Ban
-  [Letter](#) Regarding MD PDAB UPL Setting
-  [Letter](#) in Support of WA Legislature Expanding Access to Obesity Treatment Coverage
-  [Letter](#) in Support of Transparency in AI Use in Prior Authorizations in WA
-  [Letter](#) in Support of WA Expanding Primary Care Reporting Requirements and Health Expenditure Data
-  [Letter](#) in Support of WA Establishing Rare Disease Advisory Council
-  [Letter](#) to VA on PDAB Bill
-  [Letter](#) to MD PDAB on Rules
-  [Letter](#) in Support of TN Biomarker Legislation
-  [Letter](#) in Support of OR Biomarker Legislation
-  [Comment](#) to OR PDAB on Drug Review Process
-  [Letter](#) Opposing NV MFP Bill
-  [Letter](#) in Support of Step Therapy Ban for Serious Mental Illness in NJ
-  [Letter](#) to WV Regarding PDAB
-  [Letter](#) to MI Regarding PDAB
-  [Letter](#) to KS Regarding PDAB
-  [Letter](#) to IL Regarding PDAB
-  [Letter](#) to CO PDAB on UPL for Enbrel
-  [Letter](#) to OR PDAB Regarding Use of UPL
-  [Letter](#) to LA Department of Insurance Regarding Access to Long-Acting Treatments and “Convenience”
-  [Follow-Up Letter](#) to the MI Department of Insurance Regarding the Authority to Enforce 2020 NBPP
-  [Letter](#) to MD PDAB on Data and Patient Input
-  [Letter](#) Urging SMI Step Therapy Ban in NY
-  [Letter](#) Urging SMI Step Therapy Ban in MN
-  [Letter](#) to WA Health Care Authority Regarding ANP Scope of Practice and Prior Authorization Policies
-  [Letter](#) to MS Department of Insurance Regarding “Never Medically Necessary” Designation for Long-Acting Treatments
-  [Letter](#) to CO Legislator Regarding AFP Bill
-  [Letter](#) to FL Humana Regarding Mandated Brown-Bagging Policy
-  [Letter](#) to Oscar Insurance Regarding Mandated Brown-Bagging Policy
-  [Letter](#) in Support of WI Copay Accumulator Ban
-  [Letter](#) in Support of OH Copay Accumulator Ban




FEDERAL

-  [Comment](#) on CMS Proposed Obesity Coverage for Medicare and Medicaid
-  [Comment](#) on 2026 Medicare & Medicaid Rule on IRA Implications and Artificial Intelligence
-  [Letter](#) to CMS regarding IRA negotiations for 2027
-  [Letter](#) to CMS on IRA Negotiations and Transparency
-  [Letter](#) to CCIIO on EHB Rule and DOL FAQ
-  [Letter](#) Urging CMS to Clarify Benefits RFI
-  [Letter](#) Urging CMS to Impose Stronger Oversight in ACA Appeals
-  [NCL Petition](#) to FTC on Compounded GLP-1s
-  [Letter](#) Requesting FDA Clarify Use of Mandated Importation for Employees

In addition to the federal advocacy activities listed above, Aimed Alliance signed on to the Partnership to Advance Cardiovascular Health (PACH) letters on GLP-1s, the IRA, and cardiovascular treatments under the IRA; the Leukemia and Lymphoma Society's letter in support of Accelerating Kids' Timely Access to Care; Research!America's letter regarding NIH funding cuts; Value of Care Coalition's open letter on QALYs; the Everylife Foundation & NORD's letter regarding PRV reauthorization; the Movement Disorder Policy Coalition letter on durable medical equipment proposed coverage; the Alliance for Aging Research's MP3 letter; and efforts to support education on the impact of Medicaid cuts on women; the need for expanded access to adult changing tables in Capitol buildings; protecting ACIP's decision-making framework (September 2025 Meeting) and expanding biomarker access in Maryland.

Lastly, Aimed Alliance directly engaged with payers several times in 2025 to ensure they complied with state and federal patient protection laws. In 2025, Aimed Alliance sent letters to Blue Cross Blue Shield of Mississippi, Humana, and Oscar Insurance regarding coverage policies that impaired consumers' ability to access their medically necessary treatments.



LITIGATION

Recognizing the need to empower patient advocacy organizations to engage in litigation, Aimed Alliance launched two [Judicial Advocacy Working Groups](#). Led by both legal professionals and patient advocacy organizations, these working groups aim to ensure the consumer perspective is better represented across all areas of law, including litigation. To educate advocates on the types of litigation ongoing, Aimed Alliance published a Quarterly Litigation and Case Law Tracker.

[Volume 1, Issue 1](#) | [Volume 1, Issue 2](#) | [Volume 1, Issue 3](#)



RESEARCH & ANALYSIS

In 2025, Aired Alliance conducted research and provided analysis on its policy priorities, much of which was embodied in the comments and letters described above. Aired Alliance also presented its research and analysis in reports, fact sheets, brochures, and legislative maps. Our research and analysis activities in 2025 included the following:

RESOURCES



Know Your Rights

[Step Therapy Reform:](#)

Aired Alliance developed a fact sheet explaining the new step therapy law passed in New York during the 2024 legislative session. [English](#)

[Open Enrollment](#)

Aired Alliance published the following consumer and employer resources in 2025 to help consumers have access to, find, and enroll in an appropriate health insurance plan.



[Open Enrollment: Understanding Your Health Plan and Your Cost-Sharing Responsibilities](#)

This brochure is most suitable for individuals in individual and small group health plans purchased through state marketplace exchanges (*sometimes referred to as Healthcare.gov or Obamacare plans*).



[2026 Medicare Open Enrollment: Understanding Your Medicare Plan and Your Cost-Sharing Responsibilities](#)

This brochure is most suitable for Medicare beneficiaries, including those who select plans with Original Medicare and Medicare Advantage.



[Open Enrollment: Selecting Benefits for Your Employees to Protect Their Health](#)

This brochure is most suitable for human resources professionals.

REPORTS & FACT SHEETS

Aimed Alliance regularly develops focused reports and fact sheets to help educate consumers, providers, caregivers, employers, and policymakers on a variety of complex issues. Below are some of our reports, fact sheets, and additional resources from 2025:

Step Therapy



The report features an analysis of laws and trends in regulating the use of step therapy in both commercial health insurance markets and Medicaid programs; an examination of state reporting

requirements related to step therapy, internal appeals, and external appeals; a detailed analysis of proposed and enacted policies addressing the use of artificial intelligence in benefit utilization practices; and a comprehensive state-by-state breakdown of step therapy laws, oversight mechanisms, reporting requirements, and available appeals data.

[English](#)

Gold Card Laws



Since 2022, Aimed Alliance has published an annual Gold Card Tool summarizing gold card legislation across the U.S., examining both successful and unsuccessful efforts.

[2024 & 2025](#)

Menopause



[Menopause in the Workplace: Supporting Women Through Career Transitions.](#)

Aimed Alliance published an article on HR.com, authored by

Olivia Backhaus, Staff Attorney at Aimed Alliance, discussing how employers can support women in menopause in the workplace.



[Menopause and the Workplace:](#)

Menopause is a natural stage of life for women that has traditionally been ignored in the workplace and

benefits planning. Despite its widespread negative impact on well-being, engagement, and performance, menopause is often shrouded in stigma, leaving many women feeling isolated and unsupported. This infographic highlights key findings from the report.



Litigation & Case Law Tracker



Aimed Alliance's Litigation & Case Law Tracker summarizes developments in legal cases and the law that could affect the rights of U.S. health care consumers, caregivers, and providers. This quarterly publication also highlights the judicial-branch advocacy efforts of Aimed Alliance and other not-for-profit organizations.

quaterly publication also highlights the judicial-branch advocacy efforts of Aimed Alliance and other not-for-profit organizations.

[Volume 1, Issue 1](#)

[Volume 1, Issue 2](#)

[Volume 1, Issue 3](#)

Judicial Advocacy




Aimed Alliance's [Judicial Advocacy Working Group](#) serves as a convening space for advocacy organizations that want to better understand and engage in judicial advocacy to protect and expand health care access and coverage.

International Drug Pricing



Tariffs 101: How Tariffs Could Impact Patients.

This resource is designed to help educate health care advocates and consumers on how tariffs could impact consumers and health care affordability.



The Art of the Trade: Understanding the USTR.

For many patients, providers, and caregivers, the USTR is an unfamiliar federal office they likely haven't interacted with. This resource aims to inform stakeholders about the USTR's role, its influence on prescription drug affordability, and how consumers and advocates can effectively engage this office.

resource aims to inform stakeholders about the USTR's role, its influence on prescription drug affordability, and how consumers and advocates can effectively engage this office.




Drug Pricing & PBM Reform



Pharmacy Benefit Managers: Their Role, Impact, and the Need for Reform.

This resource is designed to help patients, providers, and health care advocates understand

the role of PBMs, how they impact drug costs and access, and why reform is needed. It also explains how PBMs operate, the challenges they pose, proposed reforms, and where those reforms have been adopted across states.



The 340B Program Explained: Access, Impact, and the Road to Reform.

This resource educates stakeholders on the elements of the 340B program and how the various reforms would

impact diverse health care stakeholders such as patients, providers, covered entities, and pharmaceutical manufacturers.

STATE MAPS Bills & Laws

Aimed Alliance regularly tracks and monitors state-based legislation that would improve consumers' access to medically necessary treatments and alleviate administrative burdens on providers. Our 2025 legislative tracking included the following maps:

- ▶ **Step Therapy** [Active & Enacted](#)
- ▶ **Prior Authorization** [Active & Enacted](#)
- ▶ **Copay Accumulators** [Active & Enacted](#)
- ▶ **Biomarkers Maps** [Active & Enacted](#)
- ▶ **Non-medical Switching** [Active & Enacted](#)
- ▶ **Oral Parity Maps** [Active & Enacted](#)

Aimed Alliance is expanding our work in 2026! [Sign up for the monthly Aimed Alliance newsletter](#) to ensure you don't miss anything.



Thought LEADERSHIP

Using its research and analysis, Aimed Alliance develops sound, patient-centered policy recommendations. Representatives for the organization disseminate messages by interacting with the news media and presenting to audiences of patients, advocates, practitioners, human resource professionals, policymakers, and the public. In 2025, our thought leadership included:

SPOTLIGHT PRESENTATIONS:

Copay Accumulators/Non-EHB/Alternative Funding Programs:

To inform consumers, employers, providers, and caregivers about the impacts of copay accumulators, non-EHB programs, and AFPs on patients, Aimed Alliance hosted a series of webinars on these issues. These webinars provided patient and health care professional perspectives, legal and regulatory analysis, and employer insights on the impacts of these programs.

- ▶ Aimed Alliance, Speaker, "Alternative Funding Programs," at [Frier Leavitt](#).
- ▶ Aimed Alliance, Moderator, "Copays Kill: How Cost Sharing Undermines Health," at [BIO International 2025](#).
- ▶ Aimed Alliance, Presenter, "Alternative Funding Programs," at [Informa Connect's Patient Assistance & Access Conference](#).
- ▶ Aimed Alliance, Panelist, "Alternative Funding Programs," at [National Council of Insurance Legislators Summer 2025 Meeting](#).
- ▶ Aimed Alliance, Panelist, "Alternative Funding Programs," at [BIO Coffee Chat: The State of Patient Access](#).
- ▶ Aimed Alliance, Speaker, "Alternative Funding Programs," at [AiArthritis Patient Education Series](#).
- ▶ Aimed Alliance, Panelist, "Cracking the Code: Understanding Copay Accumulators, Maximizers and Alternative Funding," at [Nexus AMCP 2025](#).
- ▶ Aimed Alliance, Panelist, "Alternative Funding Programs," at [Informa Connect's PBM Contracting Summit](#).



Prescription Drug Pricing and Pharmacy Benefit Manager (PBM) Reform:

To inform legislatures, advocates, and advocacy organizations about the complexity of prescription drug costs, PBMs, and other health insurance practices that can impact health care consumers, Aimed Alliance hosted and participated in a variety of webinars and panels discussing these complex issues.

- ▶ Aimed Alliance, Speaker, "Pharmacy Benefit Managers," at [Virginia Association of Hematologists and Oncologists](#).
- ▶ Aimed Alliance, Panelist, "Patient Access in the U.S. and Abroad," at [BIO 2025 Patient Advocacy Changemakers Event](#).

Innovation:

Aimed Alliance believes that the costs of health care treatments and services should be reasonable and transparent. Value and innovation relate to the value that is assigned to a treatment or medical service, the process by which that value is calculated, and the costs that consumers incur to access those treatments and services.

- ▶ Aimed Alliance, Panelist, "Capitol Conversations: Maintaining Investments in New Innovation (MINI) Act," at [Healthy Women: Capitol Conversations](#).
- ▶ Aimed Alliance, Panelist, "MINI Act" at [National Governors Association](#).



Utilization Management Reform

Aimed Alliance envisions a society in which consumers, in consultation with their health care providers and loved ones, can make informed and individually appropriate decisions about their health care, without having those decisions overridden by third parties. Access topics relate to an individual's ability to obtain the health care services that he or she needs, when the individual needs them. Third-party payers often erect barriers, known as utilization management policies, that stand between a patient and his or her ability to access medically necessary health care services. These barriers are discussed among these Access topics.

- ▶ Aimed Alliance, Speaker, "Harnessing AI & Evaluating Health Benefits," at [National Foundation for Women Legislators Healthcare Summit](#).
- ▶ Aimed Alliance, Speaker, "Step Therapy and AI," at [Democratic Legislative Campaign Committee \(DLCC\) Annual Meeting](#).
- ▶ Aimed Alliance, Panelist, "Prior Authorization and Step Therapy's Impact on Medicaid Patients and Government Spending," at [Council of State Governments West \(CSG West\) 78th Annual Meeting](#).
- ▶ Aimed Alliance, Moderator, "Prior Authorization," at [Informa Connect's PBM Contracting Summit](#).



Patient Education & Advocacy:

Aimed Alliance recognizes in the importance of ensuring consumers, advocates, caregivers, and advocacy organizations are aware of their rights and opportunities to be involved in health policy at the state and federal levels.

- ▶ Aimed Alliance, Panelist, "The Secret of Success: How to Start – and Thrive – as a Patient Advocacy Organization," at [BIO Coffee Chat](#).
- ▶ Aimed Alliance, Speaker, "Health Policy 101," at [The Stephanie Wynn Foundation](#).
- ▶ Aimed Alliance, Speaker, "Health Policy 101," at [KIF1A.ORG 2025 Conference](#).
- ▶ Aimed Alliance, Speaker, "Judicial Advocacy 101," at [Aimed Alliance](#).
- ▶ Aimed Alliance, Panelist, "Women's Health," at [Capitol Hill Club](#).
- ▶ Aimed Alliance, Panelist, "From Policy to Practice: Safeguarding Patient Access in a Shifting Landscape," at [Tigerlily Foundation's Third Annual BEACON Symposium](#).
- ▶ Aimed Alliance, Panelist, "Deceptive Advertising of Compounded GLP-1 Drugs: The Need to Protect Consumers," at HECCD congressional briefing.

IN THE MEDIA

Aimed Alliance was published, quoted or recognized in the following media outlets in 2025:

- ▶ **FINANCIAL TIMES**
Small Pharma Middlemen Save Employers Money Amid Questions Over Tactics



A new wave of middlemen offers 'alternative funding' for specialty drugs. Patients bear the risks



Patients and drug makers target 'fail first' prescription model



September Coffee Chat: The State of Patient Access





Organizational **COLLABORATION**

Aimed Alliance partners with like-minded organizations whose missions align with our efforts by participating in coalitions and sharing our research and analysis at meetings and conferences. In 2025, our organizational collaboration activities included:

COALITIONS

Leader

- ▶ New York Step Therapy Alliance

Co-Chair

- ▶ Advocacy Working Group, Alternative Funding Program Taskforce

Member

- ▶ State All Copays Count Coalition
- ▶ Federal All Copays Count Coalition
- ▶ Safe Step Act Coalition
- ▶ Collaborative for Cannabinoid Science & Safety
- ▶ Ohio All Copays Count Coalition
- ▶ Ohio Biomarker Coalition
- ▶ Pennsylvania All Copays Count Coalition
- ▶ Utah All Copays Count Coalition
- ▶ New York Biomarker Coalition
- ▶ Patient Advocacy Leaders and Drug Development Industry Network (PALADIN)



Looking **AHEAD**

In 2026, Aimed Alliance will build upon past achievements with new projects that advance the interests of health care consumers and providers nationwide. We will continue our outreach to employers regarding employee health benefits; tracking of active legislation, enacted laws, and health care reform lawsuits; and projects focused on access to care, copay accumulator programs, mental health, value-based initiatives, and stopping discrimination in the workplace. We will also be expanding our work to engage in a variety of issues relating to artificial intelligence, international drug pricing, and other new and emerging issues.



To stay up to date on our health policy activities, sign up for our monthly newsletter at aimedalliance.org/newsletters, and follow us on social media:



@aimedalliance



facebook.com/aimedalliance



@aimedalliance



linkedin.com/company/aimedalliance

1455 Pennsylvania Avenue NW, Suite 400 • Washington, DC 20004
(202) 349-4089 • AimedAlliance.org

© 2026 Aimed Alliance. All Right Reserved.